The cost–effectiveness of irbesartan for hypertension

References

• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005;112:3547-53
   PubMed Web of Science ®Google Scholar
• Tocci G, Borghi C, Volpe M. Clinical management of patients with hypertension and high cardiovascular risk: main results of an Italian survey on blood pressure control. High Blood Press Cardiovasc Prev 2014;21(2):107-17
   PubMedGoogle Scholar
• Tocci G, Cicero AF, Salvetti M, et al. Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey. J Hum Hypertens 2014. [Epub ahead of print]
   Google Scholar
• Robles NR, Cerezo I, Hernandez-Gallego R. Renin-angiotensin system blocking drugs. J Cardiovasc Pharmacol Ther 2014;19(1):14-33
   PubMedGoogle Scholar
• Borghi C, Cicero AF. The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review. High Blood Press Cardiovasc Prev 2012;19(1):19-31
   PubMedGoogle Scholar
• Ribstein J, Sissmann J, Picard A, et al. Effects of the angiotensin-II antagonist SR47436 (BMS 186295) on the pressor response to exogenous angiotensin-II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens 1994;12:131
   Google Scholar
• Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999;33:850-5
   PubMed Web of Science ®Google Scholar
• Schmitt F, Martinez F, Brillet G, et al. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects. J Cardiovasc Pharmacol 1998;31:314-21
   PubMedGoogle Scholar
• Chung O, Csikós T, Unger T. Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertens 1999;13(Suppl 1):S11-20
   Google Scholar
• Vachharajani NN, Shyu WC, Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 1998;38:702-207
   PubMedGoogle Scholar
• Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998;26:408-17
   PubMed Web of Science ®Google Scholar
• Marino M, Vachharajani N. Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol 2002;40:112-22
   PubMed Web of Science ®Google Scholar
• Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997;15:1511-18
   PubMed Web of Science ®Google Scholar
• Pool JL, Guthrie RM, Littlejohn TW3rd, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462-70
   PubMed Web of Science ®Google Scholar
• Guthrie R, Saini R, Herman T, et al. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: a double-blind, placebo-controlled, dose-titration study. Clin Drug Invest 1998;15:217-27
   Web of Science ®Google Scholar
• Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension. An integrated analysis. Hypertension 1998;31:1311-16
   PubMed Web of Science ®Google Scholar
• Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53
   PubMed Web of Science ®Google Scholar
• Oparil S, Guthrie R, Lewin AJ, et al. An elective titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan. Clin Ther 1998;20:398-409
   PubMed Web of Science ®Google Scholar
• Mancia G, Korlipara K, van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002;7:1-8
   PubMedGoogle Scholar
• Bobrie G, Delonca J, Moulin C, et al. Comparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the Treatment of Mild-to-Moderate Hypertension (COSIMA) Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005;18(11):1482-8
   PubMedGoogle Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640-5
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014;23(1):3-16
   PubMed Web of Science ®Google Scholar
• Liakos CI, Grassos CA, Babalis DK. 2013 ESH/ESC Guidelines for the management of arterial hypertension: what has changed in daily clinical practice? High Blood Press Cardiovasc Prev 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Kjeldsen SE, Aksnes TA, Ruilope LM. Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D 2014;14(2):31-43
   PubMedGoogle Scholar
• Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Hypertension 2008;52:1009-11
   PubMedGoogle Scholar
• Israili ZH, Lyoussi B, Hernandez-Hernandez R, Velasco M. Metabolic syndrome: treatment of hypertensive patients. Am J Ther 2007;14:386-402
   PubMedGoogle Scholar
• Sowers JR, Neutel JM, Saunders E, et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens 2006;8:470-80
   PubMedGoogle Scholar
• Parhofer KG, Birkeland KI, DeFronzo R, et al. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). Int J Clin Pract 2010;64(2):160-8
   PubMedGoogle Scholar
• Parhofer KG, Münzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. Cardiovasc Diabetol 2007;6:36
   PubMed Web of Science ®Google Scholar
• Baumhäkel M, Schlimmer N, Böhm M; DO-IT Investigators. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008;20(5):493-500
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7
   PubMed Web of Science ®Google Scholar
• Bakris GL, Stockert J, Molitch M, et al. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009;11:177-87
   PubMedGoogle Scholar
• Kintscher U, Foryst-Ludwig A, Unger T. Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets 2008;12:1257-63
   PubMed Web of Science ®Google Scholar
• Erbe DV, Gartrell K, Zhang YL, et al. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006;45(3):154-62
   PubMed Web of Science ®Google Scholar
• Kintscher U, Bramlage P, Paar WD, et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007;6:12
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003;26:3296-302
   PubMedGoogle Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-9
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19(6):1167-76
   PubMed Web of Science ®Google Scholar
• Gaudio C, Ferri FM, Giovannini M, et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003;42:622-8
   PubMed Web of Science ®Google Scholar
• Mörtsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med 2007;261(5):472-9
   PubMedGoogle Scholar
• Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359(23):2456-67
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved Trial. Lancet 2003;362:777-81
   PubMed Web of Science ®Google Scholar
• Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45
   PubMed Web of Science ®Google Scholar
• Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007;369(9579):2079-87
   PubMed Web of Science ®Google Scholar
• Dilaveris P, Giannopoulos G, Synetos A, Stefanadis C. The role of renin angiotensin system blockade in the treatment of atrial fibrillation. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:387-403
   PubMedGoogle Scholar
• Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55(21):2299-307
   PubMed Web of Science ®Google Scholar
• Zaman AG, Kearney MT, Schecter C, et al. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004;147:823-7
   PubMedGoogle Scholar
• Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long lasting FA: a randomized prospective study. Circulation 2002;106:331-6
   PubMed Web of Science ®Google Scholar
• Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006;48(3):385-91
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-75
   PubMed Web of Science ®Google Scholar
• Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101(22):2612-17
   PubMed Web of Science ®Google Scholar
• ACTIVE I Investigators. Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364(10):928-38
   PubMedGoogle Scholar
• Bristol Myers Squibb Co. Avapro (irbesartan) United States prescribing information. Bristol Myers Squibb Co., Princeton, NJ, USA. Last text revision 2005. Available from: www.bms.com [Accessed 31 March 2006]
   Google Scholar
• Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004;64:999-1028
   PubMed Web of Science ®Google Scholar
• Simon TA, Gelarden RT, Freitag SA, et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998;82(2):179-82
   PubMed Web of Science ®Google Scholar
• Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review. Cardiovasc Diabetol 2009;8:18
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Di Martino M, Saragoni S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens 2004;6(2):76-84
   Google Scholar
• Palmer AJ, Annemans L, Roze S. Cost-effectiveness analysis of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: The Italian perspective. Pharmaeconomics 2005;7:43-57
   Google Scholar
• Coyle D, Rodby R, Soroka S, et al. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. Clin Ther 2007;29(7):1508-23
   PubMedGoogle Scholar
• Ravera M, Ratto E, Vettoretti S, et al. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol 2005;16:s48-52
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Ekman M, Fragoulakis V, et al. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Eur J Health Econ 2011;12(3):253-61
   PubMedGoogle Scholar
• Gialama F, Maniadakis N. Comprehensive overview: efficacy, tolerability, and cost effectiveness of irbesartan. Vasc Health Risk Manag 2013;9:575-92
   PubMedGoogle Scholar
• Haller H, Ito S, Izzo JLJr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364(10):907-17
   PubMed Web of Science ®Google Scholar
• Bilous R, Chaturvedi N, Sjølie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-20
   PubMed Web of Science ®Google Scholar